Clinical Trial Update: Second-Line Irinotecan vs. ILF for AGC [Phase 2]

View source ↗

Summary

A Phase 2 trial update comparing second-line Irinotecan against the ILF regimen for advanced/metastatic gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Gachon University Gil Medical Center | Conditions: Stomach Neoplasm, Metastatic | Phase 2 | Status: UNKNOWN